Analytical Data
-
基因名
HLA-A*02:01&B2M&HBV(FLLTRILTI) Monomer
- Application
-
别名
hepatitis B virus
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
A0A140T913 (G25-T305)&P61769
-
表达区间
A0A140T913 (G25-T305)&P61769 (I21-M119)&FLLTRILTI
-
分子量
52-62 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01/B2M/HBV (FLLTRILTI) monomer is a critical focus of research in the field of immunology and infectious diseases, particularly concerning Hepatitis B virus (HBV). HLA-A*02:01 is one of the most common human leukocyte antigen (HLA) class I molecules, playing a vital role in the immune response by presenting peptides derived from intracellular proteins to CD8+ T cells. The HBV peptide FLLTRILTI, derived from the HBV surface protein, is notorious for its immunogenic properties, making it a prime candidate for therapeutic vaccination strategies. Researchers are investigating the structural and functional characteristics of the HLA-A*02:01/B2M/HBV monomer to better understand how it presents viral antigens and how it can be exploited for vaccine development or T-cell-based therapies for chronic HBV infection. This research aims to improve the management and treatment outcomes for patients, as chronic HBV infection can lead to severe complications, including liver cirrhosis and hepatocellular carcinoma. By elucidating the interaction dynamics between the HLA molecule and the HBV peptide, scientists hope to identify potential targets for immunotherapy, thereby contributing to the development of innovative strategies to combat HBV-related diseases.
